BioSpace News Archive

To this day, no one knows for certain what caused the liver and kidney disease that led to Ludwig van Beethoven’s untimely death.

Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 beginning at 1:30 p.m. Eastern Time.

Profound Medical Corp. is pleased to announce that a total of 25 paper, poster and podium presentations highlighting the Transurethral Ultrasound Ablation procedure’s ability to effectively, safely and efficiently treat an unrivaled variety of prostate cancer and/or benign prostatic hyperplasia patients have been made at major medical meetings already in 2024.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced the conversion of an additional $15 million of its term loan with entities affiliated with CRG Servicing LLC into T2 Biosystems equity.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced unaudited financial and operational results for the first quarter ended March 31, 2024.

TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today it will host a conference call and webcast on May 15, 2024, at 9:00 a.m. ET to discuss financial results for the first quarter ended March 31, 2024, and provide a business update.

Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2024.

Ocular Therapeutix, Inc. announced that it has agreed to grant inducement awards to its newly appointed Vice President, Head of Programming & Data Operations, Xiaopeng “Jeff” Cai, MS; its newly appointed Vice President, Head of Biostatistics, Zhongwen “Justin” Tang, Ph.D.; and eleven other newly hired employees.

Remidio Inc., a health technology innovator developing cutting-edge technology to combat global blindness from Diabetic Retinopathy, Glaucoma, AMD, & Cataracts, is all set to achieve a significant milestone.

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense.